biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
17:44 Lab study points to a protein that may help drive aging in testicles✦17:43 Trial will test whether stool-transplant capsules slow aging in 68 adults✦17:39 Novartis pill cut MS relapses more than an older drug in two big trials✦11:36 Women on menopause hormones lost a bit more weight on Ozempic-style drugs✦05:37 Sugar found mostly in red meat tied to higher diabetes risk in early study✦05:34 AI readings of heart MRIs slightly beat doctors at flagging death risk✦17:39 Drug that cut an inherited cholesterol particle missed its main heart goal✦11:39 Breast cancer drug shrank tumors in 5 of 10 after Enhertu, makers say✦17:44 Lab study points to a protein that may help drive aging in testicles✦17:43 Trial will test whether stool-transplant capsules slow aging in 68 adults✦17:39 Novartis pill cut MS relapses more than an older drug in two big trials✦11:36 Women on menopause hormones lost a bit more weight on Ozempic-style drugs✦05:37 Sugar found mostly in red meat tied to higher diabetes risk in early study✦05:34 AI readings of heart MRIs slightly beat doctors at flagging death risk✦17:39 Drug that cut an inherited cholesterol particle missed its main heart goal✦11:39 Breast cancer drug shrank tumors in 5 of 10 after Enhertu, makers say
← All story threadsSTORY THREAD

Drugs that lower Lp(a), an inherited cholesterol particle.

1 report so far. New developments are added to this thread as they happen.

  1. Nov 2, 2026
    BIG HEART TRIAL OF NOVARTIS DRUG MISSES ITS MAIN GOALMaker's data · 8,323 people

    Drug that cut an inherited cholesterol particle missed its main heart goal

    In a trial of 8,323 people with heart disease, Novartis and Ionis's drug lowered Lp(a) but did not significantly reduce a combined measure of heart events. Full results are still to come.